Status In progress
Process STA
ID number 1085

Provisional Schedule

Expected publication 28 March 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors AbbVie (glecaprevir-pibrentasvir)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Hepatitis C Trust
Professional groups British Association for the Study of the Liver
  British Infection Association
  British Society of Gastroenterology
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Comparator companies AbbVie (ombitasvir-paritaprevir-ritonavir, and dasabuvir)
  Bristol-Myers Squibb (CAU not returned, not participating)
  Gilead Sciences
  Janssen (simeprevir)
  Meda Pharmaceuticals (CAU not returned, not participating)
  Merck Sharp & Dohme
  Mylan UK (CAU not returned, not participating)
  Roche Products (CAU not returned, not participating)
  Teva UK (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
26 October 2017 Committee meeting: 1
31 May 2017 In progress, Invitation to participate
31 May 2017 Invitation to participate
24 January 2017 - 21 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance